PMC:7080035 / 10073-11260 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T73","span":{"begin":173,"end":188},"obj":"Body_part"},{"id":"T74","span":{"begin":289,"end":304},"obj":"Body_part"},{"id":"T75","span":{"begin":353,"end":357},"obj":"Body_part"}],"attributes":[{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma7311"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma27360"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T62","span":{"begin":289,"end":304},"obj":"Body_part"},{"id":"T63","span":{"begin":289,"end":293},"obj":"Body_part"},{"id":"T64","span":{"begin":294,"end":304},"obj":"Body_part"},{"id":"T65","span":{"begin":353,"end":357},"obj":"Body_part"}],"attributes":[{"id":"A62","pred":"uberon_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/UBERON_0008946"},{"id":"A63","pred":"uberon_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A64","pred":"uberon_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/UBERON_0000353"},{"id":"A65","pred":"uberon_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T37","span":{"begin":353,"end":366},"obj":"Disease"},{"id":"T38","span":{"begin":372,"end":378},"obj":"Disease"},{"id":"T39","span":{"begin":473,"end":481},"obj":"Disease"},{"id":"T40","span":{"begin":492,"end":502},"obj":"Disease"},{"id":"T41","span":{"begin":633,"end":642},"obj":"Disease"},{"id":"T42","span":{"begin":667,"end":675},"obj":"Disease"},{"id":"T43","span":{"begin":676,"end":686},"obj":"Disease"},{"id":"T44","span":{"begin":720,"end":735},"obj":"Disease"},{"id":"T45","span":{"begin":933,"end":941},"obj":"Disease"},{"id":"T46","span":{"begin":952,"end":965},"obj":"Disease"},{"id":"T47","span":{"begin":1156,"end":1164},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005833"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0002052"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T122","span":{"begin":227,"end":228},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T123","span":{"begin":258,"end":259},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T124","span":{"begin":289,"end":293},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T125","span":{"begin":289,"end":293},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T126","span":{"begin":353,"end":357},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T127","span":{"begin":353,"end":357},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T128","span":{"begin":512,"end":513},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T129","span":{"begin":643,"end":648},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T130","span":{"begin":1011,"end":1016},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T131","span":{"begin":1017,"end":1025},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9443"},{"id":"T132","span":{"begin":1165,"end":1168},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T43","span":{"begin":234,"end":240},"obj":"Chemical"},{"id":"T44","span":{"begin":440,"end":446},"obj":"Chemical"},{"id":"T45","span":{"begin":753,"end":756},"obj":"Chemical"}],"attributes":[{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_35204"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_35204"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_131701"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T39","span":{"begin":353,"end":366},"obj":"Phenotype"},{"id":"T40","span":{"begin":482,"end":502},"obj":"Phenotype"},{"id":"T41","span":{"begin":720,"end":735},"obj":"Phenotype"},{"id":"T42","span":{"begin":952,"end":965},"obj":"Phenotype"}],"attributes":[{"id":"A39","pred":"hp_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/HP_0002088"},{"id":"A40","pred":"hp_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/HP_0006532"},{"id":"A41","pred":"hp_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/HP_0002716"},{"id":"A42","pred":"hp_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/HP_0002840"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T10","span":{"begin":241,"end":247},"obj":"http://purl.obolibrary.org/obo/GO_0098739"},{"id":"T11","span":{"begin":241,"end":247},"obj":"http://purl.obolibrary.org/obo/GO_0098657"},{"id":"T12","span":{"begin":447,"end":453},"obj":"http://purl.obolibrary.org/obo/GO_0098739"},{"id":"T13","span":{"begin":447,"end":453},"obj":"http://purl.obolibrary.org/obo/GO_0098657"},{"id":"T14","span":{"begin":801,"end":807},"obj":"http://purl.obolibrary.org/obo/GO_0098739"},{"id":"T15","span":{"begin":801,"end":807},"obj":"http://purl.obolibrary.org/obo/GO_0098657"},{"id":"T16","span":{"begin":1179,"end":1186},"obj":"http://purl.obolibrary.org/obo/GO_0009606"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-sentences","denotations":[{"id":"T87","span":{"begin":0,"end":189},"obj":"Sentence"},{"id":"T88","span":{"begin":190,"end":248},"obj":"Sentence"},{"id":"T89","span":{"begin":249,"end":430},"obj":"Sentence"},{"id":"T90","span":{"begin":431,"end":657},"obj":"Sentence"},{"id":"T91","span":{"begin":658,"end":831},"obj":"Sentence"},{"id":"T92","span":{"begin":832,"end":1050},"obj":"Sentence"},{"id":"T93","span":{"begin":1051,"end":1187},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"2_test","denotations":[{"id":"32088847-31524673-29170378","span":{"begin":368,"end":369},"obj":"31524673"},{"id":"32088847-29473946-29170379","span":{"begin":427,"end":428},"obj":"29473946"},{"id":"32088847-26573211-29170380","span":{"begin":650,"end":651},"obj":"26573211"},{"id":"32088847-22911695-29170381","span":{"begin":653,"end":655},"obj":"22911695"},{"id":"32088847-26573211-29170382","span":{"begin":1047,"end":1048},"obj":"26573211"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"LitCovid-PubTator","denotations":[{"id":"240","span":{"begin":852,"end":857},"obj":"Gene"},{"id":"241","span":{"begin":791,"end":796},"obj":"Gene"},{"id":"242","span":{"begin":619,"end":623},"obj":"Species"},{"id":"243","span":{"begin":633,"end":648},"obj":"Species"},{"id":"244","span":{"begin":1011,"end":1016},"obj":"Species"},{"id":"245","span":{"begin":1037,"end":1045},"obj":"Species"},{"id":"246","span":{"begin":1131,"end":1139},"obj":"Species"},{"id":"247","span":{"begin":745,"end":752},"obj":"Chemical"},{"id":"248","span":{"begin":797,"end":800},"obj":"Chemical"},{"id":"249","span":{"begin":343,"end":366},"obj":"Disease"},{"id":"250","span":{"begin":372,"end":378},"obj":"Disease"},{"id":"251","span":{"begin":473,"end":481},"obj":"Disease"},{"id":"252","span":{"begin":482,"end":502},"obj":"Disease"},{"id":"253","span":{"begin":579,"end":611},"obj":"Disease"},{"id":"254","span":{"begin":667,"end":675},"obj":"Disease"},{"id":"255","span":{"begin":676,"end":686},"obj":"Disease"},{"id":"256","span":{"begin":720,"end":735},"obj":"Disease"},{"id":"257","span":{"begin":933,"end":941},"obj":"Disease"},{"id":"258","span":{"begin":952,"end":965},"obj":"Disease"},{"id":"259","span":{"begin":1156,"end":1164},"obj":"Disease"}],"attributes":[{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"Gene:4838"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"Gene:4838"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"Tax:114727"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"Tax:11308"},{"id":"A244","pred":"tao:has_database_id","subj":"244","obj":"Tax:9606"},{"id":"A245","pred":"tao:has_database_id","subj":"245","obj":"Tax:1335626"},{"id":"A246","pred":"tao:has_database_id","subj":"246","obj":"Tax:9606"},{"id":"A247","pred":"tao:has_database_id","subj":"247","obj":"MESH:D019788"},{"id":"A248","pred":"tao:has_database_id","subj":"248","obj":"MESH:D019788"},{"id":"A249","pred":"tao:has_database_id","subj":"249","obj":"MESH:D008171"},{"id":"A250","pred":"tao:has_database_id","subj":"250","obj":"MESH:D009369"},{"id":"A251","pred":"tao:has_database_id","subj":"251","obj":"MESH:C000657245"},{"id":"A252","pred":"tao:has_database_id","subj":"252","obj":"MESH:D012141"},{"id":"A253","pred":"tao:has_database_id","subj":"253","obj":"MESH:D018352"},{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"MESH:C000657245"},{"id":"A255","pred":"tao:has_database_id","subj":"255","obj":"MESH:D007239"},{"id":"A256","pred":"tao:has_database_id","subj":"256","obj":"MESH:D008206"},{"id":"A257","pred":"tao:has_database_id","subj":"257","obj":"MESH:C000657245"},{"id":"A258","pred":"tao:has_database_id","subj":"258","obj":"MESH:D008199"},{"id":"A259","pred":"tao:has_database_id","subj":"259","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}

{"project":"MyTest","denotations":[{"id":"32088847-31524673-29170378","span":{"begin":368,"end":369},"obj":"31524673"},{"id":"32088847-29473946-29170379","span":{"begin":427,"end":428},"obj":"29473946"},{"id":"32088847-26573211-29170380","span":{"begin":650,"end":651},"obj":"26573211"},{"id":"32088847-22911695-29170381","span":{"begin":653,"end":655},"obj":"22911695"},{"id":"32088847-26573211-29170382","span":{"begin":1047,"end":1048},"obj":"26573211"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"In accordance with previously published observations [5, 6], our cases were characterized by the presence of peripheral GGOs and/or consolidative opacities in more than two pulmonary lobes. Notably, all of these lesions showed a high tracer uptake. Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [7], tumors presenting as GGOs are unlikely to be FDG-avid [8]. The high tracer uptake that characterized COVID-19 pulmonary infections reflects a significant inflammatory burden, similar to that elicited by the Middle East respiratory syndrome or the H1N1 pandemic influenza virus [9, 10]. Although COVID-19 infections do not seem to be accompanied by lymphadenopathy [6], our 18F-FDG PET/CT findings revealed an increased nodal FDG uptake in three of four cases. Although no obvious nodal enlargement was evident, our imaging data indicate for the first time that COVID-19 may cause lymphadenitis—in line with previous data obtained from non-human primates exposed to MERS-CoV [9]. Another interesting finding is that no disseminated lesions were evident in our patients—suggesting that COVID-19 has pulmonary tropism."}